GlassScriptPhysician profile
Richard Sawyers
NPI 1144421686
$583.28
in general payments reported to CMS, 2019-2025
9 companies · $218 in 2025
The $218 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $181 · 2020: $16.40 · 2023: $149 · 2024: $19.04 · 2025: $218.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $386.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $385.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Argenx US, INC. | $177.74 | 2025 | Vyvgart, Vyvgart Hytrulo |
| Abbvie INC. | $163.34 | 2019-2023 | Ubrelvy, Qulipta, Viberzi |
| Acorda Therapeutics, INC | $103.18 | 2019 | |
| Ge Healthcare | $35.55 | 2020-2025 | |
| Acadia Pharmaceuticals INC | $29.98 | 2019 | |
| Supernus Pharmaceuticals, INC. | $22.09 | 2019 | |
| Novartis Pharmaceuticals Corporation | $20.99 | 2025 | |
| Antares Pharma, INC. | $19.04 | 2024 | Xyosted |
| Genzyme Corporation | $11.37 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Sawyers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.